Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
Journal of Thoracic Oncology · 2026-05 · 21 (5) · 103541
DOI: 10.1016/j.jtho.2025.12.080 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Thoracic Oncology, 2026-05. Verfasst von David Planchard und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Paris, France. Elect…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
INTRODUCTION: HER2-directed treatments for HER2-overexpressing (HER2-OE; immunohistochemistry [IHC] 3+/2+) NSCLC are needed. METHODS: DESTINY-Lung03 is an open-label, multi-arm, phase 1b study. Part 1 evaluated trastuzumab deruxtecan (T-DXd, 4.4 or 5.4 mg/kg) plus durvalumab (1120 mg) and cisplatin (60 or 75 mg/m2; Arm 1A)/carboplatin (area under the plasma concentration-time curve [AUC] 4 or 5; Arm 1B) or T-DXd 5.4 mg/kg monotherapy (Arm 1D) in pretreated metastatic HER2-OE NSCLC. Primary end points: dose-limiting toxicities (DLTs) and adverse events (AEs: Arms 1A and 1B). Secondary end points: safety (Arm 1D) and efficacy (all arms). RESULTS: At data cutoff (April 1, 2024), 11, 24, and 36 patients received treatment in Arms 1A, 1B, and 1D, respectively. DLTs reported in Arm 1A: febrile neutropenia (n = 1; grade [G] 5; 4.4 mg/kg/1120 mg/60 mg/m2 doses); decreased platelet count (n = 2; G4 and G5; 5.4 mg/kg/1120 mg/75 mg/m2 doses). DLTs reported in Arm 1B: febrile neutropenia (n = 1; G3; 4.4 mg/kg/1120 mg/AUC 5 doses; n = 1; G4; 4.4 mg/kg/1120 mg/AUC 4 doses); decreased platelet count (n = 1; G4; 5.4 mg/kg/1120 mg/AUC 5 doses). Drug-related serious AEs occurred in 63.6%, 37.5%, and 16.7% of Arms 1A, 1B, and 1D, respectively. Confirmed objective response rate (95% confidence interval) per investigator: 37.5% (18.8-59.4; Arm 1B) and 44.4% (27.9-61.9; Arm 1D). CONCLUSIONS: Data confirm the activity of T-DXd monotherapy in pretreated HER2-OE NSCLC but do not support T-DXd plus durvalumab and platinum chemotherapy use in this population. GOV IDENTIFIER: NCT04686305.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Paris, France. Electronic address: David.PLANCHARD@gustaveroussy.fr.
- Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea.
- Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Section of Medical Oncology, St Luke's Medical Center, Metro Manila, Philippines.
- Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, Italy; Department of Medicine, University of Milano-Bicocca, Milan, Italy.
- Center for Lung Cancer, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea.
Förderung
- AstraZeneca
Zitieren
APA
Planchard, D., Kim, H. R., Suksombooncharoen, T., Li, R., Cortinovis, D., Han, J. Y., Samol, J., Runglodvatana, Y., Lee, K. Y., Chang, G. C., Lee, C. H., Kowalski, D., Saw, S. P. L., Huang, Y., Ruiter, G., Ahn, M. J., Yang, T. Y., Yang, C. T., Sookprasert, A., …, & Yang, J. C. (2026). Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. Journal of Thoracic Oncology, 21(5), 103541. https://doi.org/10.1016/j.jtho.2025.12.080
Vancouver
Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, et al. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. Journal of Thoracic Oncology. 2026;21(5):103541. doi:10.1016/j.jtho.2025.12.080
BibTeX
@article{Planchard2026,
author = {Planchard, David and Kim, Hye Ryun and Suksombooncharoen, Thatthan and Li, Rubi and Cortinovis, Diego and Han, Ji-Youn and Samol, Jens and Runglodvatana, Yotsawaj and Lee, Kang-Yun and Chang, Gee-Chen and Lee, Chun-Hui and Kowalski, Dariusz and Saw, Stephanie P L and Huang, Yiqing and Ruiter, Gerrina and Ahn, Myung-Ju and Yang, Tsung-Ying and Yang, Cheng-Ta and Sookprasert, Aumkhae and Nakajima, Erica C and Alfon, Jose and McEwen, Robert and Chang, Yi-Ting and Yang, James Ch},
title = {Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial},
journal = {Journal of Thoracic Oncology},
year = {2026},
volume = {21},
number = {5},
pages = {103541},
doi = {10.1016/j.jtho.2025.12.080}
}
EUVIMED